{"id":1571,"date":"2017-11-07T08:00:30","date_gmt":"2017-11-07T16:00:30","guid":{"rendered":"http:\/\/iqbiosciences.com\/?p=1571"},"modified":"2021-12-19T13:23:59","modified_gmt":"2021-12-19T21:23:59","slug":"ting-it-up-for-bispecific-antibodies-part-1","status":"publish","type":"post","link":"https:\/\/iqbiosciences.com\/blog\/ting-it-up-for-bispecific-antibodies-part-1\/","title":{"rendered":"T’ing it Up for Bi-Specific Antibodies\u2026(Part 1)"},"content":{"rendered":"

\"\"<\/p>\n

With the current trend of developing immunotherapies for cancer, many of these therapies center on exploiting the potent effector functions of lymphocytes, specifically T cells.\u00a0 In our previous blogs<\/a>, we introduced a new class of therapeutic molecules called bi-specific antibodies and discussed their mechanism of action for anti-cancer therapy.\u00a0 In this blog, we will discuss in vitro<\/em> assays that use T cells to develop bi-specific antibody programs.<\/p>\n

What are CD4 and CD8 T cells?<\/h3>\n

In most organismal immune systems, there are two main types of T cells.\u00a0 One type is the CD4 T cell, which is a hematopoietic cell that develops in the thymus and subsequently activates the immune system to mount an immune response.\u00a0 This cell becomes activated after binding the target cell, which then leads to the secretion of numerous cytokines that activate and potentiate the immune response.\u00a0 These cytokines include IFN-g, TNF-a, IL-2, IL-12, and IL-23.<\/p>\n

CD4 cells are characterized by the presence of the CD4 marker and CD3\/T cell receptor (TCR) complex on the surface of the cells.\u00a0 In a normal scenario, a T cell begins to secrete cytokines after engagement of its CD3\/TCR complex to MHC class I protein on a target cell.<\/p>\n

The other main type of T cell is the CD8 T cell, which also develops in the thymus.\u00a0 In contrast to mature CD4 cells, CD8 cells survey the body for aberrant cells, such as those that are infected or cancerous, to eliminate them.\u00a0 These cells perform their effector function by binding the target cell and secreting cytolytic molecules toward it, which leads to cell death.\u00a0 These molecules, which include perforin and granzyme, create holes in the target cells to permit entry of proteases that promote programmed cell death.<\/p>\n

CD8 T cells can be identified by the presence of the CD8 marker and CD3\/T cell receptor (TCR) complex on the surface of the cells.\u00a0 These cells are typically activated to kill upon engagement of their CD3\/TCR complex to the MHC class I protein presenting foreign antigen on the target cells.<\/p>\n

Because of these abilities to promote the immune response and perform cytotoxicity to eliminate aberrant cells, T cells are often exploited in cancer immunotherapies, such as bi-specific antibodies, checkpoint inhibitors, and genetically engineered T cells (CAR T cells<\/a>).\u00a0 Therefore, T cells are important components in the testing and development of these therapies.<\/p>\n

What are some T cell-based in vitro<\/em> assays to assess bi-specific antibody specificity and function?<\/h3>\n

Bi-specific antibodies that exploit T cells often bring the T cell into close proximity with the target cell.\u00a0 Therefore, one arm of the bi-specific antibody must bind a marker expressed on the T cell surface, which in most cases is the CD8 or CD3 molecule.\u00a0 For development of these bi-specific antibodies, one type of required assay is the T cell binding assay to ensure the bi-specific antibody is binding the correct cell type.\u00a0 Typically, the assay is flow cytometry-based and performed with PBMCs, an assortment of cell-specific antibodies, and the bi-specific antibody.\u00a0 The data are then analyzed to determine the cell type that binds the bi-specific antibody, which should be T cells.\u00a0 Therefore, both CD4 and CD8 T cells are used for this binding assay.<\/p>\n

Another in vitro<\/em> assay commonly used in preclinical studies are functional studies that determine if the CD8 T cells are killing their targets. \u00a0These cytolytic cells are mixed with targets in the presence of the bi-specific antibody and then assessed for cell death of the targets using various readouts.\u00a0 One method for assaying cytotoxicity is labeling target cells with Calcein, which is released upon cell death, and then measuring the amount of Calcein present in the supernatant of the culture.\u00a0 Another method uses flow cytometry.\u00a0 In this assay, the targets are also labeled with an intracellular dye and then assessed for death by the loss of the labeled target cells in the culture.<\/p>\n

To focus on CD4 T cell function and bi-specific antibodies, one commonly performed assay is the cytokine release assay (CRA)<\/a>.\u00a0 These studies assess whether the antibody activates CD4 cells to promote cytokine secretion.\u00a0 Here, CD4 cells are mixed with targets in the presence of the bi-specific antibody and then the supernatant is collected and assessed for the presence of cytokines using a cytokine bead array (CBA) kit.\u00a0 This kit permits the interrogation of a number of different cytokines that may be produced.<\/p>\n

With these T cell-based assays, investigators can perform pre-clinical studies to investigate the specificity and function of T cells in relation to bi-specific antibodies.\u00a0 Immunology-based CROs, such as iQ Biosciences, can assist researchers in determining which T cell types and assays will help in development of their bi-specific antibody.\u00a0 Contact<\/a> iQ Biosciences for more information.<\/p>\n

In our next blog, we will discuss T cell-based in vivo<\/em> assays to assess the efficacy of bi-specific antibodies. Furthermore, we will review in vitro<\/em> and in vivo<\/em> data from some of our studies that put these T cell-based assays into context.<\/p>\n","protected":false},"excerpt":{"rendered":"

With the current trend of developing immunotherapies for cancer, many of these therapies center on exploiting the potent effector functions of lymphocytes, specifically T cells.\u00a0 In our previous blogs, we introduced a new class of therapeutic molecules called bi-specific antibodies and discussed their mechanism of action for anti-cancer therapy.\u00a0 In this blog, we will discuss in vitro assays that use T cells to develop bi-specific antibody programs. What are CD4 and CD8 T cells? In most organismal immune systems, there are two main types of T cells.\u00a0 One type is the CD4 T cell, which is a hematopoietic cell that […]<\/p>\n","protected":false},"author":70,"featured_media":1583,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pg_page_styles":[],"inline_featured_image":false,"footnotes":""},"categories":[177,1,187],"tags":[],"yoast_head":"\nT'ing it Up for Bi-Specific Antibodies\u2026(Part 1) | iQ Biosciences<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/iqbiosciences.com\/blog\/ting-it-up-for-bispecific-antibodies-part-1\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"T'ing it Up for Bi-Specific Antibodies\u2026(Part 1) | iQ Biosciences\" \/>\n<meta property=\"og:description\" content=\"With the current trend of developing immunotherapies for cancer, many of these therapies center on exploiting the potent effector functions of lymphocytes, specifically T cells.\u00a0 In our previous blogs, we introduced a new class of therapeutic molecules called bi-specific antibodies and discussed their mechanism of action for anti-cancer therapy.\u00a0 In this blog, we will discuss in vitro assays that use T cells to develop bi-specific antibody programs. What are CD4 and CD8 T cells? In most organismal immune systems, there are two main types of T cells.\u00a0 One type is the CD4 T cell, which is a hematopoietic cell that […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/iqbiosciences.com\/blog\/ting-it-up-for-bispecific-antibodies-part-1\/\" \/>\n<meta property=\"og:site_name\" content=\"iQ Biosciences\" \/>\n<meta property=\"article:published_time\" content=\"2017-11-07T16:00:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-12-19T21:23:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/iqbiosciences.com\/wp-content\/uploads\/2017\/11\/t-cell-image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"860\" \/>\n\t<meta property=\"og:image:height\" content=\"469\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"iQ Biosciences\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"iQ Biosciences\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/iqbiosciences.com\/blog\/ting-it-up-for-bispecific-antibodies-part-1\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/iqbiosciences.com\/blog\/ting-it-up-for-bispecific-antibodies-part-1\/\"},\"author\":{\"name\":\"iQ Biosciences\",\"@id\":\"https:\/\/iqbiosciences.com\/#\/schema\/person\/072e01e7973b29eac434492d33455590\"},\"headline\":\"T’ing it Up for Bi-Specific Antibodies\u2026(Part 1)\",\"datePublished\":\"2017-11-07T16:00:30+00:00\",\"dateModified\":\"2021-12-19T21:23:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/iqbiosciences.com\/blog\/ting-it-up-for-bispecific-antibodies-part-1\/\"},\"wordCount\":832,\"publisher\":{\"@id\":\"https:\/\/iqbiosciences.com\/#organization\"},\"articleSection\":[\"Bi-specific Antibody\",\"Blog\",\"T Cells\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/iqbiosciences.com\/blog\/ting-it-up-for-bispecific-antibodies-part-1\/\",\"url\":\"https:\/\/iqbiosciences.com\/blog\/ting-it-up-for-bispecific-antibodies-part-1\/\",\"name\":\"T'ing it Up for Bi-Specific Antibodies\u2026(Part 1) | iQ Biosciences\",\"isPartOf\":{\"@id\":\"https:\/\/iqbiosciences.com\/#website\"},\"datePublished\":\"2017-11-07T16:00:30+00:00\",\"dateModified\":\"2021-12-19T21:23:59+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/iqbiosciences.com\/blog\/ting-it-up-for-bispecific-antibodies-part-1\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/iqbiosciences.com\/blog\/ting-it-up-for-bispecific-antibodies-part-1\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/iqbiosciences.com\/blog\/ting-it-up-for-bispecific-antibodies-part-1\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/iqbiosciences.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"T’ing it Up for Bi-Specific Antibodies\u2026(Part 1)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/iqbiosciences.com\/#website\",\"url\":\"https:\/\/iqbiosciences.com\/\",\"name\":\"iQ Biosciences\",\"description\":\"The smarter way.\",\"publisher\":{\"@id\":\"https:\/\/iqbiosciences.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/iqbiosciences.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/iqbiosciences.com\/#organization\",\"name\":\"iQ Biosciences\",\"url\":\"https:\/\/iqbiosciences.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/iqbiosciences.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/iqbiosciences.com\/wp-content\/uploads\/2016\/09\/logo.png\",\"contentUrl\":\"https:\/\/iqbiosciences.com\/wp-content\/uploads\/2016\/09\/logo.png\",\"width\":200,\"height\":56,\"caption\":\"iQ Biosciences\"},\"image\":{\"@id\":\"https:\/\/iqbiosciences.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.linkedin.com\/company\/iq-biosciences\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/iqbiosciences.com\/#\/schema\/person\/072e01e7973b29eac434492d33455590\",\"name\":\"iQ Biosciences\",\"url\":\"https:\/\/iqbiosciences.com\/blog\/author\/jim\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"T'ing it Up for Bi-Specific Antibodies\u2026(Part 1) | iQ Biosciences","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/iqbiosciences.com\/blog\/ting-it-up-for-bispecific-antibodies-part-1\/","og_locale":"en_US","og_type":"article","og_title":"T'ing it Up for Bi-Specific Antibodies\u2026(Part 1) | iQ Biosciences","og_description":"With the current trend of developing immunotherapies for cancer, many of these therapies center on exploiting the potent effector functions of lymphocytes, specifically T cells.\u00a0 In our previous blogs, we introduced a new class of therapeutic molecules called bi-specific antibodies and discussed their mechanism of action for anti-cancer therapy.\u00a0 In this blog, we will discuss in vitro assays that use T cells to develop bi-specific antibody programs. What are CD4 and CD8 T cells? In most organismal immune systems, there are two main types of T cells.\u00a0 One type is the CD4 T cell, which is a hematopoietic cell that […]","og_url":"https:\/\/iqbiosciences.com\/blog\/ting-it-up-for-bispecific-antibodies-part-1\/","og_site_name":"iQ Biosciences","article_published_time":"2017-11-07T16:00:30+00:00","article_modified_time":"2021-12-19T21:23:59+00:00","og_image":[{"width":860,"height":469,"url":"https:\/\/iqbiosciences.com\/wp-content\/uploads\/2017\/11\/t-cell-image.jpg","type":"image\/jpeg"}],"author":"iQ Biosciences","twitter_card":"summary_large_image","twitter_misc":{"Written by":"iQ Biosciences","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/iqbiosciences.com\/blog\/ting-it-up-for-bispecific-antibodies-part-1\/#article","isPartOf":{"@id":"https:\/\/iqbiosciences.com\/blog\/ting-it-up-for-bispecific-antibodies-part-1\/"},"author":{"name":"iQ Biosciences","@id":"https:\/\/iqbiosciences.com\/#\/schema\/person\/072e01e7973b29eac434492d33455590"},"headline":"T’ing it Up for Bi-Specific Antibodies\u2026(Part 1)","datePublished":"2017-11-07T16:00:30+00:00","dateModified":"2021-12-19T21:23:59+00:00","mainEntityOfPage":{"@id":"https:\/\/iqbiosciences.com\/blog\/ting-it-up-for-bispecific-antibodies-part-1\/"},"wordCount":832,"publisher":{"@id":"https:\/\/iqbiosciences.com\/#organization"},"articleSection":["Bi-specific Antibody","Blog","T Cells"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/iqbiosciences.com\/blog\/ting-it-up-for-bispecific-antibodies-part-1\/","url":"https:\/\/iqbiosciences.com\/blog\/ting-it-up-for-bispecific-antibodies-part-1\/","name":"T'ing it Up for Bi-Specific Antibodies\u2026(Part 1) | iQ Biosciences","isPartOf":{"@id":"https:\/\/iqbiosciences.com\/#website"},"datePublished":"2017-11-07T16:00:30+00:00","dateModified":"2021-12-19T21:23:59+00:00","breadcrumb":{"@id":"https:\/\/iqbiosciences.com\/blog\/ting-it-up-for-bispecific-antibodies-part-1\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/iqbiosciences.com\/blog\/ting-it-up-for-bispecific-antibodies-part-1\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/iqbiosciences.com\/blog\/ting-it-up-for-bispecific-antibodies-part-1\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/iqbiosciences.com\/"},{"@type":"ListItem","position":2,"name":"T’ing it Up for Bi-Specific Antibodies\u2026(Part 1)"}]},{"@type":"WebSite","@id":"https:\/\/iqbiosciences.com\/#website","url":"https:\/\/iqbiosciences.com\/","name":"iQ Biosciences","description":"The smarter way.","publisher":{"@id":"https:\/\/iqbiosciences.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/iqbiosciences.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/iqbiosciences.com\/#organization","name":"iQ Biosciences","url":"https:\/\/iqbiosciences.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/iqbiosciences.com\/#\/schema\/logo\/image\/","url":"https:\/\/iqbiosciences.com\/wp-content\/uploads\/2016\/09\/logo.png","contentUrl":"https:\/\/iqbiosciences.com\/wp-content\/uploads\/2016\/09\/logo.png","width":200,"height":56,"caption":"iQ Biosciences"},"image":{"@id":"https:\/\/iqbiosciences.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/iq-biosciences"]},{"@type":"Person","@id":"https:\/\/iqbiosciences.com\/#\/schema\/person\/072e01e7973b29eac434492d33455590","name":"iQ Biosciences","url":"https:\/\/iqbiosciences.com\/blog\/author\/jim\/"}]}},"_links":{"self":[{"href":"https:\/\/iqbiosciences.com\/wp-json\/wp\/v2\/posts\/1571"}],"collection":[{"href":"https:\/\/iqbiosciences.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/iqbiosciences.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/iqbiosciences.com\/wp-json\/wp\/v2\/users\/70"}],"replies":[{"embeddable":true,"href":"https:\/\/iqbiosciences.com\/wp-json\/wp\/v2\/comments?post=1571"}],"version-history":[{"count":1,"href":"https:\/\/iqbiosciences.com\/wp-json\/wp\/v2\/posts\/1571\/revisions"}],"predecessor-version":[{"id":5437,"href":"https:\/\/iqbiosciences.com\/wp-json\/wp\/v2\/posts\/1571\/revisions\/5437"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/iqbiosciences.com\/wp-json\/wp\/v2\/media\/1583"}],"wp:attachment":[{"href":"https:\/\/iqbiosciences.com\/wp-json\/wp\/v2\/media?parent=1571"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/iqbiosciences.com\/wp-json\/wp\/v2\/categories?post=1571"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/iqbiosciences.com\/wp-json\/wp\/v2\/tags?post=1571"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}